Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis

被引：9
|
作者：
Verstovsek, Srdan [1 ]
Tefferi, Ayalew [2 ]
Korriblau, Steven [1 ]
Thomas, Deborah [1 ]
Cortes, Jorge [1 ]
Ravandi-Kashani, Farhad [1 ]
Garcia-Manero, Guillermo [1 ]
Kantarjian, Hagop [1 ]
机构：
[1] MD Anderson Canc Ctr, Leukemia Dept, Houston, TX USA
[2] Mayo Clin, Coll Med, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3543.3543
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3543
引用
收藏
页码：1037A / 1037A
页数：1
相关论文
共 50 条
  • [1] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [2] Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Santos, Fabio P. S.
    Kantarjian, Hagop M.
    Jain, Nitin
    Manshouri, Taghi
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Kennedy, Debra
    Estrov, Zeev
    Cortes, Jorge
    Verstovsek, Srdan
    BLOOD, 2010, 115 (06) : 1131 - 1136
  • [3] A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Pardanani, Animesh D.
    Shah, Neil P.
    Sokol, Lubomir
    Wadleigh, Martha
    Gilliland, D. Gary
    List, Alan F.
    Tefferi, Ayalew
    Kantarjian, Hagop M.
    Bui, Lynne A.
    Clary, Douglas O.
    BLOOD, 2007, 110 (11) : 170A - 170A
  • [4] A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis
    DeAngelo, Daniel J.
    Tefferi, Ayalew
    Fiskus, Warren
    Mesa, Ruben A.
    Paley, Carole S.
    Wadleigh, Martha
    Snyder, David S.
    Begna, Kebede
    Ondovik, Michael S.
    Rine, Jessica
    Bhalla, Kapil N.
    BLOOD, 2010, 116 (21) : 276 - 277
  • [5] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
    Shah, Neil P.
    Olszynski, Patrycja
    Sokol, Lubomir
    Verstovsek, Srdan
    Hoffman, Ronald
    List, Alan F.
    Cortes, Jorge
    Kantadian, Hagop M.
    Gilliland, D. Gary
    Clary, Douglas O.
    Bui, Lynne A.
    Wadleigh, Martha
    BLOOD, 2008, 112 (11) : 44 - 44
  • [6] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [7] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
  • [8] A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2015, 126 (23)
  • [9] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    Quintas-Cardama, A.
    Tong, W.
    Kantarjian, H.
    Thomas, D.
    Ravandi, F.
    Kornblau, S.
    Manshouri, T.
    Cortes, J. E.
    Garcia-Manero, G.
    Verstovsek, S.
    LEUKEMIA, 2008, 22 (05) : 965 - 970
  • [10] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    A Quintás-Cardama
    W Tong
    H Kantarjian
    D Thomas
    F Ravandi
    S Kornblau
    T Manshouri
    J E Cortes
    G Garcia-Manero
    S Verstovsek
    Leukemia, 2008, 22 : 965 - 970
12345